Backedup its R&D platforms for biologics, Alphamab forms close collaboration with leading academic institutions, CROs and Pharmaceuticals/Biotech companies, domestic or abroad, to rapidly growing it innovation capability at the forefront of protein and antibody engineering. Regarding the mode of collaboration, there is no limit but flexibility. 

In 2011, Alphamab founded Dingfu Biotarget with world renowned scholar in tumor immunology. The successfully developed a few preclinical candidates in tumor immunotherapy, the hottest are since 2013. In 2013,a joint technology development center was set up to push forward close collaboration between Life Science College, Southeast University. The collaboration opened the venue for Alphamab to uptake dAb with the first IND filing scheduled. In 2014, Alphamab formed strategic alliance with SIMM (Shanghai Institute of MateriaMedica, Chinese Academy) for innovation/knowledge driven drug development. The alliance will utilize the strength of both parties and extend Alphamab's discovery scope to GPCR and ion channels. Also in 2014, Shenzhen Chipscreen and Alphamab announced the joint development of combination therapy withHDAC inhibitors and PD-L1 antibody.

In 2011, Alphamab co-founded Dingfu Biotarget Co. with world renowned scholar in tumor immunotherapy. The company successfully developed a few preclinical candidates in tumor immunotherapy, currently the hottest area. In 2013,a joint technology development center was set up to push forward close collaboration between Life Science College, Southeast University. The collaboration opened the venue for Alphamab to uptake nanobody technology with the first IND filing scheduled. In 2014, Alphamab formed strategic alliance with SIMM (Shanghai Institute of MateriaMedica, Chinese Academy) for innovation/knowledge driven drug development. The alliance will utilize the strength of both parties and extend Alphamab's discovery scope to GPCR and ion channels. In Q3 2014, Shenzhen Chipscreen and Alphamab announced the joint development of combination therapy of HDAC inhibitors and PD-L1 antibody.

Alphamab has been reaching out to MNC pharmaceuticals, e.g. Roche and Sanofi, with its Proprietary protein engineering platforms and preclinical candidates. In the other hand, Alphamab is also actively seeking in-licensing China right of novel biologics in early clinical trial. Alphamab has been gradually is reaching out to MNC pharmaceuticals, e.g. Roche and Sanofi, with itsProprietary protein engineering platforms and preclinical candidates. In the other hand, Alphamab is also actively seeking to in license China right of programs with POC clinical trial.